Dec 16 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
:
* REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA
* FULL DATA SET FROM OPEN-LABEL EXTENSION (OLE) OF RECOVER EXPECTED IN Q1 2025
* ALL THREE DOSES OF BRILAROXAZINE (15 MG, 30 MG AND 50 MG) TESTED EFFICACIOUS & GENERALLY WELL-TOLERATED
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。